Fenofibrate, an FDA approved small molecule drug for the treatment of hypertriglyceridemia and hypercholesterolemia, was inferred to directly inhibit IL17A the major IL17 pathway cytokine and was also suggested to act via the Th1response directly inhibiting expression of IFN-γ the major Th1 inducing cytokine [10]. This evidence concerns the gene IL17A and Hypercholesterolemia.